Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.5 million shares at $21, above the upwardly revised range of $19 to $20. The company had originally planned to offer the same number of shares at a range of $16 to $18, before increasing the range on Monday. The company is developing and commercializing a platform meant to incorporate next-generation sequencing, artificial intelligence, and machine learning technologies to develop precision medicine diagnostic solutions meant to treat cancer.
Read the full article: Caris Life Sciences Prices IPO at $21, Above the Upwardly Revised Range //
Source: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range